Board Meeting: 19/01/2001 - Meeting of EMAG with Equitable Board Members
19 January
2001 - Meeting of EMAG with Equitable Board Members
PRESENT: |
|
|
|
ELAS: |
Chris
Headdon (excluding Item 7), Jennie Page,
|
|
|
Alistair
Dunbar, David Thomas (Item 7 only) |
|
EMAG: |
Vincent
Nolan, Alex Henney, John Gardner |
Preliminaries
Introductions
; apology for EPHAG absence.
EMAG expressed satisfaction at the ELAS agreement to the request for funding of
Counsel's Opinion on the House of Lords decision as first proposed by Jeremy Lever
QC.
- Information
Update on Current Developments
-
Capping of Liabilities
What is the state of negotiations with GAR group (Stuart Bayliss)?
Reponse
An internal ELAS group is working on a proposal (including input from
Bayliss and other parties). ELAS is looking at ways it might involve members
in the development of the proposal.
EMAG expressed in interest in close involvement with these proposals
-
State of the selling process
Are we looking at sale of `substantially the whole of the operations'
(Chris Headdon) or `we are not talking about selling the whole package
again' (Alistair Dunbar)?
EMAG is particularly concerned about the sale of the investment management
operation for short-term gain at long-term cost to the policyholders (see
4. below). Also, is the `capping' proposal linked to a renewed attempt
to sell the business as an (ongoing) whole (as suggested in Press reports)?
Reponse
Could be anything from sale of whole of business (including demutualisation)
to sale of individual functions - sales force, investment management,
policy administration.
Sale of whole business will depend on a capping agreement. Sale of all
the operations (without demutualisation) could happen without capping.
It is hoped to announce the sales transaction in February.
Comment
EMAG favours separation of the capping proposals from sale proposals.
Once the liabilities are capped and the board reformed there may be no
need to put the business in the hands of shareholders.
-
FSA
What is the role of the FSA in 'brokering' a sale?
Reponse
It is not the role of the FSA to broker a sale. ELAS is keeping FSA informed
and FSA will review any proposals.
- Appointment
of New Chairman
Issue: how can member representatives be involved in the process of selecting
a new Chairman, prior to the AGM at which he is presented for confirmation?.
What would be the process by which member representatives could put forward
an alternative candidate for Chairman if they were not satisfied with the
candidate selected by the current (departing) Board?
Reponse
We hope to announce the preferred chairman in February. Non-executive director
Jonathan Dawson (also of Lazards and at the time of meeting out of the country)
is leading the selection panel.
Comment
EMAG is pursuing with Jonathan Dawson the process of selecting a new Chairman
- Appointment
of new Non-Executive Directors
Issue: How can member representation on the Board be achieved in both the
short and long term. EMAG believe that the Board would be strengthened by
the immediate co-option of 3 or 4 member representatives, including one representing
the interests of group schemes, to replace a corresponding number of current
(departing) members. The co-opted Directors would be either confirmed or replaced
by elected member representatives at the AGM.
Reponse
Intention is to focus on the appointment of the Chairman, who will then recruit
new non-executive Directors, until the AGM.
- Investment
Management
Issue: EMAG believe that investment management is the `core business' of a
closed company and should be under the direct control of the Board (whether
in-house or out-sourced) with the aim of maximising performance at minimum
cost to members. Alex Henney's paper proposes a rigorous audit of ELAS investment
performance on a regular basis and a careful examination of the merits of
active vs. passive management of funds
Reponse
ELAS will supply back data on investment performance to EMAG (AH) and compare
it against appropriate indices for each main category of investment. ELAS
does contribute relevant data to an independent survey (WM) which is confidential
to contributors and cannot therefore be reported to ELAS members.
Comment
EMAG has proposed a regular independent audit of investment performance which
can be reported to members.
- Transparency
EMAG welcomes the Policyholder Updates advertised in the national press and
the use of the ELAS website to keep members informed and to rebut misleading
Press reports. We were promised (Dec.1st) a briefing document to accompany
the recommendation of the sale of the business, with a further more detailed
account of the Society's situation in Feb./March 2000. With the collapse of
the sale process, this information has not been forthcoming. There is still
a great deal of information the Board could usefully share with members, including
the following:
-
The methods by which the £1.5 billion liability has been estimated,
including the range of scenarios considered and assumptions made, especially
about interest rates. (It is still widely believed and reported that the
'true' liability is still substantially greater than estimated and that
prospective bidders withdrew because they believed the potential liabilities
were much greater - in spite of Chris Headdon's denial that this was the
case, at EPHAG's Dec.19th meeting). We propose that the Society should
commission a truly independent study of the liabilities (including confidential
discussions with bidders who withdrew) and publish the results of the
study.
Reponse
Details of the calculation of liabilities will be disclosed with the 'capping'
proposal to be announced probably next month.
-
Reinsurance of Liabilities:Was/is there reinsurance covering the guaranteed
annuity liability? There has been much press comment in relation to the
Irish subsidiary of GE Capital.
Reponse
Details are/will be given as required in the statutory annual accounts.
-
The costs incurred by the Society in legal expenses, advertising and sales
promotion in the period July-Dec. 2000, loyalty bonuses to the sales force
and other staff, staff performance bonuses for 2000, cost of sales force
salaries and expenses since the HoL decision. While these would normally
be left to the internal management of the Society, these are not normal
times.
Reponse
Information about legal costs, advertising expenditure etc., and other
information requested by policyholders, will be disclosed in the Annual
Report and Accounts.
|